Market cap
$139.2bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
We also signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance for reimbursement of ALYFTREK for eligible patients six years of age and older in Canada. Sickle Cell Disease and Beta Thalassemia • In the second quarter of 2026, we recorded $76.4 million of CASGEVY product revenues, representing a 78% increase compared to the first quarter of 2026 and a 151% increase compared to the second quarter of 2025 . • The U.S. Acute Pain • In the second quarter of 2026, we recorded $49.6 million of JOURNAVX product revenues, representing a 71% increase compared to the first quarter of 2026 and a more than 300% increase compared to the second quarter of 2025 . …VERTEX PHARMACEUTICALS INC / MA, 10-Q, period ended 2026-06-30, filed 2026-08-04